Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide does take a while to work, and that is by design. Most people notice their appetite beginning to change within the first few weeks, but meaningful weight loss typically builds over three to six months as the dose increases. Understanding that timeline (and what to look for along the way) is the decision this page helps you make sense of. These are prescription-only medicines; a prescriber assesses whether they are clinically right for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When semaglutide enters the picture, the body needs time to adjust to a medicine that slows gastric emptying and quiets the appetite signals that drive overeating, and how semaglutide works at a biological level helps explain why these early physical changes happen before any meaningful weight loss does. The first four weeks are spent at 0.25 mg, a dose that exists almost entirely to reduce the chance of nausea rather than to drive weight loss. Some people do notice less interest in food almost immediately. Others feel little change. Both responses are normal, and neither predicts how well the medicine will eventually work.
After four weeks the dose typically steps up to 0.5 mg, then moves toward 1.7 mg and eventually 2.4 mg (the standard maintenance dose) over subsequent months, each increase subject to how well the previous dose was tolerated. The titration schedule exists for a reason: rushing it tends to increase side effects without improving outcomes. Our detailed page on how semaglutide is used in the UK covers the licensed dose pathway in more depth.
A practical checking habit worth building in the first month: weigh yourself once a week, at the same time of day, on the same scales, and note it down. It keeps expectation honest and gives your prescriber useful information at review.
The period between weeks four and twenty-four is where most of the clinically meaningful weight loss occurs for people who respond well. As the dose climbs and the body adapts to reduced calorie intake, weight tends to fall more steadily. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults using semaglutide 2.4 mg alongside lifestyle changes over 68 weeks and found an average body-weight reduction of around 15%. That figure represents a long-run average, the weight did not drop all at once in month one.
Does Wegovy take a while to work in the same way semaglutide does in diabetes treatment? The dose pathway is the same GLP-1 mechanism, but the weight-management licence uses higher doses than those approved for type 2 diabetes, which matters for results. If you want a fuller picture of how long semaglutide takes to work and what to expect at each stage, that sits alongside the trial data as useful background reading.
Progress is rarely linear. A plateau at week ten does not mean the medicine has stopped working, it may mean your body is recalibrating before the next phase of loss. This is a common point where people consider stopping. Staying in contact with your prescriber through those quieter patches is more useful than drawing conclusions from a single fortnight on the scales.
Six months on the maintenance dose is the agreed clinical checkpoint. NICE guidance (TA875), which governs NHS prescribing of semaglutide for weight management, specifies that treatment should be reviewed and potentially stopped if weight loss remains below 5% at that stage. That threshold applies on the NHS; private prescribers apply the same clinical logic because the underlying evidence is the same. The full NICE appraisal of semaglutide sets out the reasoning if you want to read the committee's thinking directly.
For those who do respond well, weight loss tends to continue beyond six months as long as the medicine is maintained and lifestyle changes are sustained. The 15% average seen in STEP 1 was measured at 68 weeks, the longer arc matters. Our page on supporting yourself during Wegovy treatment covers the lifestyle factors that appear to make the most difference alongside the medicine.
One thing worth knowing early: semaglutide is not a short course. Stopping it tends to reverse much of the weight lost unless lifestyle habits have genuinely shifted during treatment. That is not a reason to avoid it; it is a reason to think about what you want from it before you start. Pricing context, including what a full course of private treatment involves, is covered on our Wegovy cost page.
Slow progress is a clinical question, not an emergency. If you are three months in and the scales have barely moved, that is a conversation for your prescriber at your next review, not a reason to increase your dose yourself or stop abruptly. A real clinician reads your follow-up, not an automated system, and can adjust your plan based on what has actually happened.
There are signs that need more urgent attention. Severe stomach pain that reaches through to the back, with or without vomiting, should prompt you to seek medical help promptly, the MHRA has highlighted acute pancreatitis as a known, though infrequent, risk with GLP-1 medicines. Dehydration from persistent vomiting or diarrhoea also warrants early contact with a healthcare professional. For ongoing practical guidance during treatment, our semaglutide advice page covers side effect management in detail, and the MHRA's Yellow Card scheme allows you to report any suspected reactions directly.
If you are still weighing up whether semaglutide is the right option or want to understand the full range of licensed weight-management treatments available in the UK, our weight-loss treatment overview brings everything together. And if you are ready to find out whether you are clinically suitable, you can start a free consultation with our prescribers today, reviewed the same day, no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.